Mariano Provencio
Overview
Explore the profile of Mariano Provencio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
307
Citations
9664
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Provencio M, Massuti B, Hernando-Trancho F
Lung Cancer
. 2025 Feb;
201:108419.
PMID: 39919547
No abstract available.
2.
Garitaonaindia Y, Martinez-Cutillas M, Uribarren M, Redondo I, Calvo V, Serna-Blasco R, et al.
Clin Transl Oncol
. 2025 Jan;
PMID: 39789380
This review aims to summarize recent studies and findings within adoptive cell therapies, including tumor-infiltrating lymphocytes, genetically engineered T cell receptors, and chimeric antigen receptor T cells, in the treatment...
3.
Rios-Sanchez B, Vigueras G, Garcia A, Gomez-Bravo D, Menasalvas E, Torrente M, et al.
Data Brief
. 2024 Dec;
57:111167.
PMID: 39736907
This dataset comprises information about 1242 lung cancer patients collected by the Medical Oncology Department of the Puerta de Hierro University Hospital of Majadahonda in Madrid, Spain. It includes information...
4.
Garcia-Simon N, Valentin F, Royuela A, Hidalgo-Calero B, Blazquez-Martin R, de-Miguel-Reyes M, et al.
Clin Transl Oncol
. 2024 Dec;
PMID: 39661238
Background: APC and MUTYH genes are key in hereditary attenuated adenomatous polyposis syndromes. Guidelines recommend genetic testing based on polyp count, often overlooking age despite its impact on polyp prevalence....
5.
Echepare M, Picabea B, Arricibita A, Teijeira A, Pasquier A, Zandueta C, et al.
J Thorac Oncol
. 2024 Nov;
20(3):345-365.
PMID: 39536877
Introduction: Chemotherapy continues to be the standard treatment for patients noneligible for targeted or immune-based therapies; nevertheless, treatment resistance remains a major clinical challenge. We previously found that expression levels...
6.
Garcia-Barragan A, Sakor A, Vidal M, Menasalvas E, Gonzalez J, Provencio M, et al.
Med Biol Eng Comput
. 2024 Nov;
63(3):749-772.
PMID: 39485651
Accurate recognition and linking of oncologic entities in clinical notes is essential for extracting insights across cancer research, patient care, clinical decision-making, and treatment optimization. We present the Neuro-Symbolic System...
7.
Molina-Alejandre M, Perea F, Calvo V, Martinez-Toledo C, Nadal E, Sierra-Rodero B, et al.
J Immunother Cancer
. 2024 Oct;
12(10).
PMID: 39428126
Background: Loss of human leukocyte antigen (HLA) class I expression and loss of heterozygosity (LOH) are common events implicated in the primary resistance of non-small cell lung cancer (NSCLC) to...
8.
Provencio M, Nadal E, Insa A, Campelo R, Casal J, Domine M, et al.
Lancet Oncol
. 2024 Oct;
25(11):1453-1464.
PMID: 39419061
Background: Perioperative immunotherapy improves short-term outcomes in resectable non-small-cell lung cancer (NSCLC). We now report 5-year survival from the NADIM trial to assess its long-term benefit. Methods: NADIM was a...
9.
Provencio M, Arenas-Jimenez J, Cilleruelo Ramos A, Fernandez Villar A, Gomez Caamano A, Guirado M, et al.
Clin Transl Oncol
. 2024 Oct;
PMID: 39354268
In Spain, lung cancer (LC) is the fourth most common cancer. Managing LC involves different professionals, and cooperative and coordinated work is crucial. Therefore, important decisions are better made by...
10.
Soo R, Dafni U, Han J, Cho B, Nadal E, Yeo C, et al.
Clin Cancer Res
. 2024 Sep;
30(22):5180-5191.
PMID: 39250635
Purpose: The ETOP 10-16 BOOSTER study was a randomized phase II trial of osimertinib and bevacizumab therapy versus osimertinib therapy in patients with an acquired EGFR T790M mutation. The mechanisms...